ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients

Simone Cesaro1*, Tina Dalianis2, Christine Hanssen Rinaldo3,4, Minna Koskenvuo5, Anna Pegoraro1, Hermann Einsele6, Catherine Cordonnier7 and Hans H. Hirsch8,9† on behalf of the 6th European Conference on Infections in Leukaemia (ECIL-6‡), a joint venture of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS), and the European Leukaemia Net (ELN)

1Pediatric Hematology-Oncology, Azienda Ospedaliera Universitaria Integrata Verona, Italy; 2Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden; 3Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway; 4Metabolic and Renal Research Group, UIT The Arctic University of Norway, Tromsø, Norway; 5Division of Hematology-Oncology and Stem Cell Transplantation, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Finland; 6Department of Internal Medicine II, University Hospital Würzburg, Julius Maximilians University Würzburg, Germany; 7Assistance Publique-Hôpitaux de Paris, Henri Mondor Teaching Hospital, Department of Hematology, 94000 Créteil, Paris-Est Créteil (UPEC) University, Créteil; 8Transplantation & Clinical Virology, Department Biomedicine (Haus Petersplatz), University of Basel, Petersplatz 10; CH-4009 Basel, Switzerland; 9Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland

*Corresponding author. Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, P.le A. Stefani 1, 37126, Verona, Italy. Tel: +39-045-8127874; Fax +39-045-8126326; E-mail: simone.cesaro@aovr.veneto.it
†These authors made an equal contribution.
‡ECIL-6 members are listed in the Acknowledgements section.

Objectives: To define guidelines for BK polyomavirus (BKPyV)-associated haemorrhagic cystitis (BKPyV-HC) after paediatric and adult HSCT.


Results: BKPyV-HC occurs in 8%–25% of paediatric and 7%–54% of adult recipients undergoing allogeneic HSCT. Diagnosis requires the triad of cystitis, macro-haematuria and high urine BKPyV loads >7 log10 copies/mL, and exclusion of other relevant aetiologies. BKPyV viraemia is frequent and may serve as a more specific semiquantitative follow-up marker. No randomized controlled trials are available to inform antiviral prophylaxis or treatment. However, hyper-hydration and/or bladder irrigation showed limited prophylactic value. Fluoroquinolones are not effective for prophylaxis or treatment, but rather increase antibiotic resistance. Hyperbaric oxygen or fibrin glue is marginally effective based on small case series from correspondingly equipped centres. Although cidofovir has been reported to improve and/or reduce BKPyV viraemia or viruria, the current data do not support its regular use.

Conclusions: BKPyV-HC remains a disabling unmet clinical need in HSCT that requires novel approaches supported by proper clinical trials.

Introduction

Haemorrhagic cystitis (HC) is a significant complication after HSCT, the incidence ranging from 2% to 66% according to the type and procedure of HSCT and the age of the patients. HC contributes to post-HSCT morbidity by prolonging hospital stay and severely worsening the quality of life, but its role in increasing post-HSCT mortality is controversial.1–4 Several factors contribute to the appearance of HC, which is also reflected in the classification based on the time of onset in the post-HSCT course. Early-onset HC is defined as occurring within ~1 week of HSCT, typically during or within 48 h of conditioning and is considered to result largely from direct toxicity of the conditioning regimen on the urothelial mucosa, particularly from drug metabolites and radiotherapy. Urothelial damage is worsened by inflammation leading to
haemorrhagic leakage aggravated by impaired coagulation and thrombocytopenia.

Late-onset HC, on the other hand, usually starts around the time of neutrophil engraftment, particularly in the setting of allogeneic HSCT, but can be observed from 2 weeks up to the first 6 months post-HSCT,\(^1,5-10\) and is mostly associated with high-level BK polyomavirus (BKPyV) replication. BKPyV is one of 13 known human polyomavirus species.\(^5,11\) The discovery of BKPyV dates back to 1971 when it was isolated from the urine of the kidney transplant patient B.K., shedding epithelial cells with nuclear viral inclusions, so-called ‘decoy cells.’\(^11,12\) A consistent link of BKPyV to disease was missing until identifying its role in HC after HSCT,\(^6,7\) and nephropathy after kidney transplantation.\(^13-15\) We summarize the biology, epidemiology and clinical characteristics of BKPyV-HC in haematology patients and provide recommendations that were discussed and approved at the 6th meeting of the European Conference on Infectious Disease in Leukaemia (ECIL-6)\(^16\) held on 11–12 September 2015 in Sophia Antipolis, France.

Background

ECIL is a joint initiative supported by the European Leukaemia Network, the Infectious Diseases Working Party of the European Association for Blood and Marrow Transplantation (IDWP-EBMT), the Infectious Disease Group of European Organization for Research and Treatment of Cancer, and the Immunocompromised Host Society (ICHIS). For the 6th edition, the ECIL Board decided to address BKPyV and endorsed a panel of experts to review the paediatric and adult literature and propose guidelines for affected haematology patients. The panel included two members of the ECIL Board (S. C., H. E.) and four European experts on BKPyV [T. D., C. H. R., M. K., H. H. H. (IDWP-EBMT member and current ICHS president elect)]. The ECIL-6 Consensus Conference was attended by 55 participants from 24 countries (18 European countries, 6 non-European countries). The supporting scientific societies contributed to the selection of participants by proposing 10 members each, whereas the ECIL board invited the remaining participants based on their scientific and/or clinical expertise in managing infectious complications in haematology patients.

Literature search

The literature search was performed by S. C. and A. P. using the following terms in PubMed: BK polyomavirus, haemorrhagic cystitis, and haematopoietic peripheral stem cell or bone marrow, or cord blood transplantation. Studies published until 31 August 2015 regarding biology and mechanism of pathogenesis of BKPyV as well as diagnosis, prophylaxis, and therapy of BKPyV-HC were identified, missing papers were added, and all were reviewed by all panel experts. The results of the literature search and a preliminary draft of recommendations for diagnosis, prophylaxis and treatment of BKPyV-HC were presented to the ECIL-6 conference for discussion and approval. The final recommendations were graded according to the ECIL-6 evidence-based medicine grading system, presented in Table 1.\(^17\) An update of the search was performed on 24 January 2017, but was not found to change the current recommendations. A schematic representation of the BKPyV virion structure is shown in Figure 1 and its genome organization is shown in Figure S1 (available as Supplementary data at JAC Online).

<table>
<thead>
<tr>
<th>Grading</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality of evidence</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Evidence from at least 1 properly designed, randomized, controlled trial (oriented at primary endpoint of the trial).</td>
</tr>
<tr>
<td>II (r, t, h, u, a)(^5)</td>
<td>Evidence from at least 1 well-designed clinical trial (including secondary endpoints) without randomization; from cohort or case-control studies (preferably from (&gt;1) centre); from multiple time series; or from dramatic results of uncontrolled experiments.</td>
</tr>
<tr>
<td>III</td>
<td>Evidence from opinions of respected authorities, based on clinical experience, descriptive case studies or report of expert committees.</td>
</tr>
</tbody>
</table>

Strength of recommendation

<table>
<thead>
<tr>
<th>Strength of recommendation</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>ECIL strongly supports a recommendation for use.</td>
</tr>
<tr>
<td>B</td>
<td>ECIL moderately supports a recommendation for use.</td>
</tr>
<tr>
<td>C</td>
<td>ECIL marginally supports a recommendation for use.</td>
</tr>
<tr>
<td>D</td>
<td>ECIL supports a recommendation against use.</td>
</tr>
</tbody>
</table>

\(^5\)Level II evidence abbreviations: r, meta-analysis or systematic review of randomized controlled trial; t, transferred evidence, i.e. results from different patient cohorts or similar immune status situation; h, comparator group was historical control; u, uncontrolled trials; a, published abstract presented at an international symposium or meeting.

An overview of BKPyV biology, immune response and disease is given in the Supplementary data.

BKPyV-HC pathogenesis, clinical presentation and diagnosis

BKPyV-HC is rare in haematology patients other than those undergoing allogeneic HSCT. BKPyV-HC occurs between 2 and 8 weeks (range 1 week–6 months) after HSCT, typically starting during the peri-engraftment period, and should be distinguished from an early-onset HC (\(<1\) week after HSCT) caused by toxicity of the conditioning regimen such as cyclophosphamide and busulfan, or total body irradiation.\(^18-21\) In HSCT patients, high-level BKPyV viruria > 7 log\(_{10}\) genome equivalents (gEq)/mL is associated with an increased risk for BKPyV-HC.\(^22-24\) However, high-level BKPyV viruria is not specific for BKPyV-HC, as >80% of all HSCT patients develop high-level BKPyV viruria, while only 5%–20% develop BKPyV-HC.\(^2,21\) High-level BKPyV viruria and BKPyV-HC are mainly observed in allogeneic HSCT patients receiving full conditioning and an unrelated human leucocyte antigen mismatched donor.\(^25-27\) Adenovirus, herpes simplex virus, JC polyomavirus, cytomegalovirus (CMV) and other infectious (bacteria, parasite) and non-infectious aetiologies...
bleeding disorders with or without low platelet count, primary or metastatic neoplasia, vesical catheter or ureteric stenting) may also cause HC, and must be excluded for appropriate diagnosis and management.4,28–30 The severity of haematuria is commonly described as microscopic (grade 1); macroscopic (grade 2); macroscopic with clots (grade 3); or macroscopic with clots and post-renal failure secondary to urinary tract obstruction (grade 4).4,21 Thus, the diagnosis of BKPyV-HC requires the triad of: (i) clinical symptoms/signs of cystitis, such as dysuria and lower abdominal pain; (ii) a haematuria grade 2 or higher; and (iii) the demonstration of BKPyV viruria, with viral loads of $7 \log_{10}$ copies/mL (Table 2).

Plasma viral loads of $3–4 \log_{10}$ copies/mL are seen in more than two-thirds of episodes of BKPyV haemorrhagic cystitis.

Epidemiology and risk factors for BKPyV-HC
The observed incidence of BKPyV-HC is 8%–25% and 7%–54% in paediatric and adult patients, respectively, being higher after allogeneic than after autologous HSCT and particularly after haploidentical HSCT with post-transplant exposure to cyclophosphamide as prophylaxis for graft versus host disease (GVHD) (Table 3).1,3,23,25,33,40–48 The lower incidence in autologous HSCT may reflect the role of immunosuppression and GVHD in allogeneic HSCT for BKPyV-HC pathogenesis.5 Table 4 shows the main risk factors of BKPyV-HC. High-level BKPyV viruria and viraemia have both been reported as predictive factors for BKPyV-HC in patients receiving allogeneic HSCT.1,3,8,9,23,25,30,33,40,41,49 In a paediatric study a urine BKPyV load of $10^4$ gEq/mL had a sensitivity of 86% and specificity of 60%, while a blood BKPyV load of $10^3$ gEq/mL had a sensitivity of 100% and a specificity of 86% for HC, respectively.3

Table 2. Triad of diagnostic criteria for BKPyV haemorrhagic cystitis

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>clinical symptoms/signs of cystitis, such as dysuria and lower abdominal pain</td>
</tr>
<tr>
<td>2</td>
<td>haematuria grade 2 or higher</td>
</tr>
<tr>
<td>3</td>
<td>BKPyV viruria of $7 \log_{10}$ copies/mL</td>
</tr>
</tbody>
</table>

*Plasma viral loads of $3–4 \log_{10}$ copies/mL are found in more than two-thirds of episodes of BKPyV haemorrhagic cystitis.*

Figure 1. BK polyomavirus structure. Polyomavirus virions are small (40–45 nm), non-enveloped, and environmentally stable. Capsid consists of the structural protein VP1 on the outside and VP2 and VP3 proteins on the inside accommodating the circular 5.1 kb double-stranded DNA genome. Diagram on left summarizes the structure of the virus. Image on right is a transmission electron micrograph of purified BK polyomavirus after negative staining with 2% uranyl acetate. This figure appears in colour in the online version of *JAC* and in black and white in the print version of *JAC.*
BKPyV IgG levels have been low or undetectable in paediatric HSCT patients with BKPyV-HC, but the current data do not permit the use of BKPyV antibody titres to predict risk of BKPyV-HC. Single studies have reported CMV or human herpesvirus (HHV)-6 viraemia as independent risk factors for BKPyV-HC. Furthermore, the stem cell source affects the risk of BKPyV-HC. Patients receiving cord blood units and peripheral blood stem cells have a higher risk of developing BKPyV-HC compared with patients receiving bone marrow grafts. Unrelated donors and GVHD have been associated with BKPyV-HC in line with the notion that the altered alloimmune immune control contributes to pathogenesis. Unrelated donors and GVHD have been associated with a higher cumulative incidence compared with mismatched or matched related donors as well as acute GVHD grade II–IV alone or combined with high-level BKPyV viruria. The intensity of the conditioning regimen was also found to have an impact. Myeloablative conditioning resulted in a higher risk compared with reduced intensity conditioning, with agents such as cyclophosphamide, high-dose busulfan and anti-thymocyte globulin being independent risk factors. Notably, the age of the HSCT recipient was evaluated and patients >7 years of age had a greater risk for BKPyV-HC than younger children.

### Prophylaxis for BKPyV-HC

The prevention of HC including BKPyV-HC, has been explored using non-specific measures such as hyperhydration and bladder irrigation. In a prospective, randomized study comparing hyperhydration plus forced diuresis with standard hydration plus mesna during the conditioning regimen, the incidence of HC was 4% in the hyperhydration arm and 6% in the standard hydration arm.

---

### Table 3: Incidence of BKPyV-HC according to type of transplant and patient age

<table>
<thead>
<tr>
<th>Setting</th>
<th>Percentage incidence, median (range)</th>
<th>No. of patients</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allo-HSCT</td>
<td>13 (7–25)</td>
<td>2096</td>
<td>1, 23, 3, 10, 25, 33, 41–45, 76</td>
</tr>
<tr>
<td>Haplo-HSCT with post-transplant cyclophosphamide exposure</td>
<td>24.5 (19–54)</td>
<td>179</td>
<td>46, 61, 47, 48</td>
</tr>
<tr>
<td>Auto-HSCT</td>
<td>0</td>
<td>118</td>
<td>43</td>
</tr>
<tr>
<td>Adults</td>
<td>16 (7–54)</td>
<td>1413</td>
<td>3, 46, 42, 45, 47, 48, 76, 91</td>
</tr>
<tr>
<td>Children</td>
<td>18 (8–25)</td>
<td>724</td>
<td>3, 40, 33, 61, 43, 44</td>
</tr>
<tr>
<td>Adult and paediatric population</td>
<td>16 (13–19)</td>
<td>206</td>
<td>23, 25</td>
</tr>
</tbody>
</table>

Allo-HSCT: allogeneic HSCT; Haplo-HSCT: haploidentical HSCT; auto-HSCT, autologous HSCT.

### Table 4: Summary of the main risk factors for development of BKPyV-HC

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>No. of studies</th>
<th>HSCT type/total no. patients</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>BKPyV positivity in urine</td>
<td>6</td>
<td>Allo-HSCT/507</td>
<td>1, 8, 23, 25, 30, 33, 40, 41, 49</td>
</tr>
<tr>
<td>BKPyV positivity in blood</td>
<td>5</td>
<td>Allo-HSCT/426; Auto-HSCT/25</td>
<td>30, 33</td>
</tr>
<tr>
<td>Other viraemia</td>
<td>30, 33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CMV</td>
<td>1</td>
<td>Allo-HSCT/50</td>
<td>3</td>
</tr>
<tr>
<td>HHV-6</td>
<td>1</td>
<td>Allo-HSCT/88</td>
<td>23, 45, 49</td>
</tr>
<tr>
<td>Stem cell source</td>
<td>3, 45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UCB</td>
<td>2</td>
<td>Allo-HSCT/814</td>
<td>3</td>
</tr>
<tr>
<td>PBSC</td>
<td>1</td>
<td>Allo-HSCT/323</td>
<td>3</td>
</tr>
<tr>
<td>Type of donor: unrelated</td>
<td>1</td>
<td>Allo-HSCT/175</td>
<td>25</td>
</tr>
<tr>
<td>Type of conditioning</td>
<td>9, 23, 45, 49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ATG</td>
<td>1</td>
<td>Allo-HSCT/90</td>
<td>9</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>1</td>
<td>Allo-HSCT/117</td>
<td>43</td>
</tr>
<tr>
<td>high-dose busulfan</td>
<td>1</td>
<td>Allo-HSCT/117</td>
<td>44</td>
</tr>
<tr>
<td>myeloablative conditioning</td>
<td>1</td>
<td>Allo-HSCT/175</td>
<td>25</td>
</tr>
<tr>
<td>Age at transplant: &gt;7 years</td>
<td>1</td>
<td>Allo-HSCT/88</td>
<td>33</td>
</tr>
</tbody>
</table>

Allo-HSCT, allogeneic HSCT; UCB, umbilical cord blood; PBSC, peripheral blood stem cells; aGVHD, acute GVHD; ATG, serum anti-thymocyte globulin.
similar in the two study arms (26.8% versus 23.7%, respectively).\textsuperscript{21} In a recent prospective study, bladder irrigation through a three-way Foley catheter did not result in an overall reduction of HC compared with a historical control group, although the mean duration of HC and of hospitalization was reduced.\textsuperscript{51} The main drawbacks of these interventions are the risk of fluid overload for hyperhydration and the invasiveness of three-way Foley positioning. Supported by in vitro data demonstrating inhibition of BKPyV replication,\textsuperscript{52,53} ciprofloxacin has been evaluated for preventing BKPyV-HC in two retrospective and one prospective cohort study with a total of 294 patients (155 treated with ciprofloxacin versus 149 not treated with ciprofloxacin).\textsuperscript{54–56} The results were inconclusive as one study showed only a reduction of BKPyV reactivation, but no difference regarding BKPyV-HC,\textsuperscript{54} while the second study reported a reduction of HC and the third study observed no impact on clinically significant HC.\textsuperscript{56} Of note, a randomized, double-blind, placebo-controlled study on 154 kidney transplant patients showed that 3 month prophylaxis with levofloxacin failed to reduce BKPyV viruria or viraemia significantly, but was associated with increased fluoroquinolone-resistant bacterial infections and an increased rate of tendinitis.\textsuperscript{57}

**Therapy of BKPyV-HC**

Cidofovir treatment of BKPyV-HC has been evaluated in 12 retrospective and 2 prospective studies with a total of 210 patients (Table 6). Cidofovir is a nucleotide analogue that inhibits a broad range of DNA viruses, and its active metabolite has a long half-life of 15–65 h that allows administration at weekly intervals. The major drawback is tubular and ocular nephrotoxicity that can be reduced by saline hydration and by probenecid, which inhibits cidofovir uptake into renal tubular epithelial cells. Although there is no agreement regarding dose, modality or frequency of administration, most authors used intravenous cidofovir 3–5 mg/kg/week or bi-weekly together with probenecid to prevent nephrotoxicity. In the absence of probenecid, cidofovir has been administered at a 3–5-fold reduced dose.\textsuperscript{58} Disregarding the study heterogeneities, a complete clinical response was reported in 74% of patients, and at least 1 log\textsubscript{10} decline in urine viral loads in 38% and in blood viral loads in 84% of patients (Table 6). Mild to moderate increases in serum creatinine concentration were seen in 18% of the patients.\textsuperscript{5,9,10,29,32,59} In four retrospective studies, 52 patients were treated with low-dose cidofovir at 0.5–1.5 mg/kg/week without probenecid, and a complete clinical response was observed in 83% of patients, a virological response in urine in 62% and in blood in 67% of cases. Also in this group of patients, a mild to moderate increase in serum creatinine concentration was reported in 20% of patients.\textsuperscript{50–53} To overcome the risk of nephrotoxicity, intravesical administration of cidofovir at the dose of 5 mg/kg/week has been reported for 14 patients showing a complete clinical response in 43% of patients and a virological response in ~50%.\textsuperscript{10,32,64,65} The use of leflunomide, an antimetabolite drug with immunomodulatory and antiviral activity, has been reported in two retrospective studies on 19 patients obtaining an overall complete and partial response rate of 63% and 26%, respectively.\textsuperscript{66,67} Finally, complete clinical response with partial or complete virological response has been reported for two patients treated with vidarabine and one case treated with oral levofloxacin.\textsuperscript{58–70} None of these studies provided a comparison with a control group to estimate a benefit over a spontaneous course and BKPyV-HC clearance.

Other treatments of BKPyV-HC aim at repair and regeneration of the urothelial mucosa through hyperbaric oxygen therapy or topical application of fibrin glue (Table 5). Hyperbaric oxygen therapy was given to a total of 29 patients in different case reports or case series, with a complete clinical response rate of 86% and reduced urine BKPyV load in 65% of patients.\textsuperscript{71–75} The main drawback of hyperbaric oxygen therapy is its limited availability on a larger scale, the requirements for dedicated hyperbaric room facilities, the risk of ear barotrauma/pressure intolerance and claustrophobia linked to the procedure. Finally, topical applications to the damaged bladder mucosa to achieve haemostasis through cystoscopy have been reported in single-centre retrospective series of 35 patients. The complete response rate was 83%.\textsuperscript{76} Similarly, several compounds to reduce bleeding have been used in case studies and small series, e.g. FXII concentrate,\textsuperscript{77} intravesical sodium hyaluronate,\textsuperscript{78,79} oestrogens\textsuperscript{80,81} or chloretol extract granules\textsuperscript{82} with

| Table 5. Level of evidence and recommendations for prophylaxis of BKPyV-HC |
|---------------------------------|-----------------|-----------------|
| **Fluoroquinolones**            | **Hyperhydration** | **Bladder irritation** |
| No. of studies | References | Type of study | Efficacy | Toxicity | No. of patients | (during conditioning) | | |
| 3 | 54–56 | Retrospective, 2; cohort-prospective, 1. | Reduction in BKPyV reactivation and HC incidence\textsuperscript{54}; no efficacy in reducing rates of clinically significant HC (1 study\textsuperscript{56}). | No adverse effects; beware bacterial resistance. | 294 (155 ciprofloxacin, 149 no ciprofloxacin). | 1 | Prospective, randomized. | 171 (71 at 2 mL/kg/h + mesna vs 76 at 4 mL/kg/h and forced diuresis). | Cohort-prospective versus historical control group. | 80 patients vs 40 patients (historical), 3-way Foley catheter used. | 1 |

No adverse effects; beware fluid retention. | 51 | No significant reduction of HC overall but significant reduction of HC 4 weeks after HSCT; reduction of mean duration of HC and hospitalization. | No adverse effects; beware, invasive procedure. |
response rates between 50% and 100%. Brincidofovir, a lipid conjugate of cidofovir, showed in vitro, on primary human urothelial cultures, a potent and long-lasting inhibitory effect on BKPyV replication, but no data are available on the clinical use for BKPyV-HC. A single case of BKPyV nephropathy after an allogeneic HSCT was reported,86 but no evidence that it has a fully established benefit in using intravenous immunoglobulin preparations for BKPyV-HC (see Table 7).

Conclusions and recommendations

BKPyV-HC remains a challenging complication after allogeneic HSCT with average rates of ~13%. A BKPyV-HC diagnosis requires the clinical and laboratory triad of cystitis, macrohaematuria and high urine BKPyV loads >7 log_{10} gEq/mL (AII h u), but a significant role of other aetiologies must be excluded. Plasma BKPyV loads >1000 gEq/mL has a role for management and follow-up of triad-positive allogeneic HSCT recipients (BII h u). Screening of asymptomatic HSCT patients at risk remains an area of investigation and is presently not recommended, as pre-emptive therapy is not established (DII).

BKPyV-HC prophylaxis relies on hyperhydration (BII t) and bladder irrigation (CII t) aiming at reducing urothelial damage, particularly when using myeloablative conditioning based on cyclophosphamide, busulfan and total body irradiation. Specific antiviral prophylaxis is not available and fluoroquinolones are not recommended given the lack of significant effects on BKPyV replication and HC severity, and the selection of antibiotic resistance (DII h t).

BKPyV-HC treatment is based on the best supportive therapy, such as hyperhydration, bladder irrigation, platelet transfusions as needed to reduce bleeding, and pain treatment (AIII). The risk/benefit ratio of reduction of immunosuppression is not clear in BKPyV-HC and must be balanced with the risk of worsening or triggering acute GVHD. Antiviral treatment with intravenous cidofovir is controversial due to the absence of randomized controlled studies. Until the availability of safe and effective antivirals, the use of cidofovir may be an option although there is uncertainty of efficacy, the dose schedule and the need to balance any benefit against its renal side effects (CII u). Non-specific measures aimed at speeding the healing process of the damaged urothelial lining such as hyperbaric oxygen therapy or urologic fibrin glue application have been successful in a limited number of uncontrolled studies (CIII). No recommendation is possible for several other treatments such as the administration of intravesical sodium hyaluronate, intravenous

---

**Table 6. Summary of studies using cidofovir for the treatment of BKPyV-HC**

<table>
<thead>
<tr>
<th>No. of studies</th>
<th>References</th>
<th>Type of study</th>
<th>No. of patients</th>
<th>Efficacy</th>
<th>Toxicity (no. episodes)</th>
<th>Virological Reduction in BKPyV loads in:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>clinical</td>
<td></td>
<td>blood: 67% (67 of 80).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>virological</td>
<td></td>
<td>urine: 62% (30 of 48); blood: 67% (8 of 12).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>transient nephrotoxicity (11).</td>
</tr>
</tbody>
</table>

CDV, cidofovir, CR, complete response; iv, intravenous; PR, partial response.

---

**Cellular therapy for BKPyV-HC**

Owing to the lack of an effective, clinically validated antiviral drug for the treatment of BKPyV-HC, cell therapy approaches have been explored. To induce tissue repair and immune modulatory and anti-inflammatory properties, third party mesenchymal stroma cells were infused into seven patients with BKPyV-HC. In five patients, haematuria resolved with few side effects. Subsequently, a prothrombotic effect of mesenchymal stroma cells was reported thus questioning this type of approach. To target BKPyV replication directly, adoptive transfer of virus-specific T cells was reported using PBMCs from 48 stem cell donors for in vitro stimulation using pools of overlapping peptide libraries covering 12 different immunogenic proteins from five different viruses, i.e. CMV, Epstein–Barr virus, adenovirus, HHV-6 and BKPyV. BKPyV-specific T cell responses were detected in 28 of the cell lines. Administration to seven allogeneic HSCT recipients with BKPyV replication demonstrated a response in six patients. Three patients with severe BKPyV-HC showed a marked symptomatic and virological response with resolution of haematuria 2–4 weeks post-treatment. No severe toxicity was reported, although a transient episode of severe bladder pain in association with inflammation was seen in one patient and treated with steroids. These results are encouraging and support further, more comprehensive studies.

---

**Review**
FXIII concentrate, leflunomide, oestrogens, mesenchymal cells and cellular immune therapy because these treatments have only been used sporadically in a very limited number of patients or are still experimental (Table 7). These evidence-based recommendations are applicable for both paediatric and adult patients.

In conclusion, despite much progress in understanding the pathogenesis, epidemiology and risk factors of BKPyV-HC, this complication still represents a disabling unmet clinical need with limited prophylactic and therapeutic options. To overcome this deficiency will require novel antiviral treatment approaches supported by proper clinical trials.

Acknowledgements
We are grateful to all members of ECIL-6 Group.

Members of the ECIL-6 Group
Murat Akova, Turkey; Mahmoud Aljurf, Saudi Arabia; Dina Averbuch, Israel; Rosemary Barnes, UK; Ola Blennow, Sweden; Pierre-Yves Bochud, Switzerland; Emilio Bouza, Spain; Stephane Bretagne, France; Roger Bruèggenmann, The Netherlands; Thierry Calandra, Switzerland; Jordi Carratala, Spain; Simone Cesaro, Italy; Catherine Cordonnier, France; Oliver Comely, Germany; Tina Dalanis, Sweden; Rafael de la Camara, Spain; Peter Donnelly, The Netherlands; Lubos Drgona, Slovakia; Rafael Duarte, Spain; Hermann Einsele, Germany; Dan Engelhard, Israel; Christopher Fox, UK; Corrado Girmenia, Italy; Andreas Groll, Germany; Dag Heldel, Norway; Jannick Helweg-Larsen, Denmark; Raoul Herbrecht, France; Hans H. Hirsch, Switzerland; Elisabeth Johnson, UK; Galina Klyasova, Russia; Minna Koskenvuo, Finland; Katrien Lagrou, Belgium; Russell E. Lewis, Italy; Per Ljungman, Sweden; Johan Maertens, Belgium; Malgorzata Mikulska, Italy; Marco Nucci, Brazil; Christophe Padoin, France; Livio Pagano, Italy; Antonio Pagliuca, UK; Zdenek Racil, Czech Republic; Patricia Ribaud, France; Christine Rinaldo, Norway; Valérie Rizzi-Puechal, France; Emmanuel Roilides, Greece; Christine Robin, France; Montserrat Rovira, Spain; Markus Rupp, Germany; Sonia Sanchez, UK; Peter Schellongowski, Austria; Peter Sediacek, Czech Republic; Jonas Sinko, Hungary; Monica Slavin, Australia; Isabella Sousa Ferreira, Portugal; Jan Styczynski, Poland; Frederic Tissot, Switzerland; Claudio Viscoli, Italy; Katherine Ward, UK; Anne-Therese Witschi, Switzerland.

Funding
The ECIL-6 meeting was supported by unrestricted educational grants from Basilea, Gilead Sciences, Merck, and Pfizer.

Transparency declarations
All authors: none to declare.

Author contributions
All authors developed the content of the manuscript. S. C. and H. H. H. drafted the manuscript, and all authors approved the final version.

Table 7. Summary recommendations for BKPyV-HC

<table>
<thead>
<tr>
<th>Topic</th>
<th>Grading</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>quantitative BKPyV viruria in allogeneic HSCT</td>
<td>AII (h u)</td>
<td>High sensitivity and high negative predictive value for a cut-off ≥ 10^7 genomic copies/mL.</td>
</tr>
<tr>
<td>BKPyV viraemia in allogeneic HSCT</td>
<td>BII (h u)</td>
<td>Some authors report a higher specificity and a positive predictive value for a cut-off &gt; 10^3–10^4 genomic copies/mL.</td>
</tr>
<tr>
<td>BKPyV viruria/viraemia screening of asymptomatic HSCT patients</td>
<td>DII</td>
<td>Not recommended outside of clinical studies due to lack of effective pre-emptive treatment.</td>
</tr>
<tr>
<td>Prophylaxis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hyper-hydration during conditioning regimen</td>
<td>BII (t)</td>
<td>To prevent the urotoxic effect on cyclophosphamide and/or busulfan.</td>
</tr>
<tr>
<td>bladder irrigation during conditioning regimen</td>
<td>CII (t)</td>
<td>Invasive procedure, discomfort for the patient.</td>
</tr>
<tr>
<td>ciprofloxacin</td>
<td>DII (h t)</td>
<td>Little effect on BKPyV replication, no effect on HC.</td>
</tr>
<tr>
<td>Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>best supportive therapy (hydration, platelet transfusion, analgesics)</td>
<td>AIII</td>
<td>Aim at higher platelet threshold for transfusions.</td>
</tr>
<tr>
<td>cidofovir intravenous</td>
<td>CII (u)</td>
<td>No recommendation on the dose (either 3–5 mg/kg every 1–2 weeks with probenecid or 0.5–1.5 mg/kg 1–3 times/week without probenecid.</td>
</tr>
<tr>
<td>fibrin glue application</td>
<td>CIII</td>
<td>Invasive procedure, cystoscopy needed.</td>
</tr>
<tr>
<td>hyperbaric oxygen therapy</td>
<td>CIII</td>
<td>Depending on local availability.</td>
</tr>
<tr>
<td>intravesical cidofovir, intravesical sodium hyaluronate, intravenous</td>
<td></td>
<td>Limited data and/or experimental procedures.</td>
</tr>
<tr>
<td>immunoglobulins, leflunomide, mesenchymal cells, adoptive immune cell therapy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HC, haemorrhagic cystitis; h, historical control group; t, transferred evidence; u, uncontrolled study.

**Supplementary data**

Table S1, Figure S1 and background information on BK polyomavirus biology appear as Supplementary data at JAC Online.

**References**


27. Dalianis T, Ljungman P. Full myeloablatative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoietic stem cell transplanted patients. *Anticancer Res* 2011; 31: 939–44.


Review


74 Savva-Bordalo J, Pinho Vaz C, Sousa M et al. Clinical effectiveness of hyperbaric oxygen therapy for BK-virus-associated hemorrhagic cystis after...


